ClinicalTrials.gg
RecruitingNCT05553223COPDUpdated Apr 4, 2025

Micro-doses of Physical Activity for COPD

An interventional study of Microdoses of activity in Chronic Obstructive Pulmonary Disease, Endothelial Dysfunction and Vascular Stiffness, sponsored by University of British Columbia. Recruiting at 1 site in Canada. Per ClinicalTrials.gov, last updated 2025-04-04.

Sponsored by University of British Columbia · Not applicable, Interventional, and Prevention

From the registry’s dates

  • Started Oct 2022; still recruiting 4 years 1 month later.
Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Randomized
Sex
All
01

Study summary

Chronic obstructive pulmonary disease (COPD) is a disease of the lungs that makes it hard for people to breath. Those with COPD spend considerably more time sitting and lying and less time performing physical activity than healthy individuals. Those who are the most sedentary have a greater risk of heart and blood vessel disease, which may lead to an early death. This project will investigate the effect of sitting still for 3 hours on blood vessel health in individuals with COPD. It will also investigate whether breaking up the amount of time patients sit with regular short bouts of walking (5 minutes each hour) at a comfortable pace chosen by the patient can have a positive effect on maintaining the health of their blood vessels. It is hypothesized that blood vessel health will be worse after 3 hours of sitting compared to when the sitting is broken up by short bouts of walking.

Read the detailed description

The Purpose of the Study:

The aim of the proposed study is to examine whether regular microdoses of low intensity physical activity (PA) can reduce the vascular dysfunction and adverse cardiovascular consequences associated with being sedentary in patients with COPD.

Hypothesis to be Tested:

Primary Hypothesis: Endothelial function (measured as superficial femoral flow mediated dilation) will be reduced in patients with COPD after 3-hours of prolonged sitting compared to the same duration of sitting interspersed with micro-doses of PA (5 min/hour of walking).

Secondary Hypothesis: Superficial femoral endothelial shear rate and antegrade blood flow will be reduced and retrograde blood flow and arterial stiffness will be increased following prolonged sitting compared to the same duration of sitting interspersed with micro-doses of PA. Mean 24-hour blood pressure will be lower when micro-doses of PA are used to reduce sedentary time.

Exploratory Hypothesis: There will be an increased release of endothelial microparticles (EMP) following prolonged sitting compared to the same duration of sitting interspersed with micro-doses of PA. Furthermore, femoral artery blood antegrade blood flow and shear rate will progressively decline, while retrograde blood flow will increase over each 30 minutes of sitting, but not when regular micro-doses of PA are performed. Flow mediated dilation will progressively decline and (EMP) release will progressively increase with each hour of sitting but not when regular micro-doses of PA are performed.

Justification: The benefits of performing regular moderate-to-vigorous intensity physical activity are well known and are associated with a lower incidence of cardio-metabolic disorders. Patients with chronic obstructive pulmonary disease generally engage in very little moderate to vigorous PA due to exertional dyspnea and typically spend a large portion of each day sitting, reclining or lying down. This increase in sedentary behaviour has been associated with vascular dysfunction, elevated blood pressure and greater risk of cardiovascular mortality in patients with COPD. As sedentary behaviour results in low global blood flow, it is an attractive postulate that one of the detrimental effects of reduced PA may be related to low vascular shear stress. More specifically, reduced shear stress has been documented to impair vascular endothelial function, promote adverse blood flow patterns (i.e. increased retrograde and reduced antegrade flow), increase vascular tone, elevate blood pressure and increase pro-atherosclerotic mediators (i.e. increased circulating levels of endothelial microparticles [EMPs] that are established markers of a dysfunctional and diseased endothelium). Growing evidence suggests that even lower intensity PA or just breaking up sedentary time may have significant health benefits. More specifically, it is feasible that increased blood flow and enhanced shear stress that occurs by moving may have a variety of cardiovascular benefits. Whether reducing sedentary time with regular short bouts (micro-doses) of low intensity PA can offset the adverse vascular consequences of prolonged sedentary behaviour in patients with COPD has not been studied.

Study Design: The study will be performed using a prospective randomized crossover design with subjects acting as their own control. After obtaining informed consent, the first visit will consist of a pulmonary function test to confirm the severity of airflow obstruction. To document current PA levels of subjects and to ensure consistency in PA between the two experimental trials, subjects will be given an accelerometer to measure their habitual physical activity levels and sedentary time on the 5 days before, and on the day of, each experimental trial. Visits 2 and 3 will then be randomized to either: 1) control - sedentary behaviour (either sitting or reclining) for 3 hours or 2) micro-doses - sedentary behavior for 3 hours with 5 minutes of walking every hour. Each visit will be separated by at least 6 days. For 24-hours before, diet will be standardized and patients will be asked to refrain from moderate-to-vigorous PA, alcohol and caffeine. Patients will come fasted (>8hr) for each visit and blood samples and vascular measurements will be made at baseline, and at 1, 2 and 3 hours of prolonged sitting. To further assess blood vessel health 24 hour ambulatory blood pressure measurements will be made following the first vascular assessment at 9am. Statistical Analysis : Data will be assessed for normalcy using a Shapiro-Wilk test. Primary and secondary outcome variables will be analyzed using linear mixed models, with repeated measures of condition (control vs. micro doses) and time (baseline vs post) as fixed factors. If significant interactions are found a Tukey post-hoc analysis will be used. The alpha level for all analysis will be set at 0.05. For the time course data linear mixed models, with repeated measures of condition (control vs. micro doses) and time (0, 1, 2, 3 hours) as fixed factors. Additionally, to assess differences between control and microdoses of PA for mean daytime, night time and nocturnal dipping blood pressures dependent t tests will be used.

02

Conditions studied

  • Chronic Obstructive Pulmonary Disease
  • Endothelial Dysfunction
  • Vascular Stiffness
  • Hypertension
  • Cardiovascular Diseases

Keywords

  • Microdoses of Physical Activity
  • Flow Mediated Dilation
  • Reactive Hyperemia
03

In context

Pulmonary Disease, Chronic Obstructive

5,520 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 856 are open to participants now.

This study's planned enrollment of 20 is below the median of 62 across 3,839 interventional studies indexed under Pulmonary Disease, Chronic Obstructive.

Browse Pulmonary Disease, Chronic Obstructive studies →

Lead sponsor

University of British Columbia is the lead sponsor of 1,339 studies on the registry; 259 are open to participants now.

Of its 6 completed or terminated interventional studies of FDA-regulated products, 1 (17%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Non-smoking (>6 months) patients with stable moderate-to-severe (post bronchodilator forced expired volume in 1 sec/forced vital capacity\<0.7 and \<lower limit of normal, 30%\<Forced Expired Volume in 1 sec\<80% predicted and exacerbation free for >6 weeks) will be recruited for the study.

Exclusion criteria

Exclusion Criteria:

  1. performing structured exercise training (or pulmonary rehabilitation)
  2. have a history of deep vein thrombosis
  3. are on anticoagulant medication
  4. have advanced cardiac or cerebrovascular disease (i.e. heart failure, previous stroke or myocardial infarction)
  5. have diabetes
  6. have musculoskeletal that limit their ability to perform physical activity
  7. vascular ultrasound measurements cannot be obtained.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Outcomes assessor)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Microdoses of Activity

    5-min bouts of walking will break up 3 hours of sitting at minutes 30, 90 and 150.

    Behavioral: Microdoses of activity

  • No intervention
    Control

    Prolonged sitting (3 hours)

Interventions

  • BehavioralMicrodoses of activity

    Short bouts of low-intensity exercise (walking) will be used to break up prolonged sitting.

06

What researchers measure

Primary outcomes

  1. Change in superficial femoral artery endothelial function

    The change in endothelial function (measured by the flow-mediated dilation response to reactive hyperaemia of the superficial femoral artery using ultrasound) from baseline to 3-hours of prolonged sitting in the control condition compared to performing 3-hours of sitting broken up by micro-doses of physical activity.

    Time frame: Within 3 hours of sitting (Day1) or within 3 hours of micro-doses of physical activity (Day 2). Days performed in a randomized order.

Secondary outcomes

  1. Difference in 24-hour ambulatory blood pressure between the two conditions

    The change in average daytime, night-time and nocturnal-dipping systolic, diastolic and mean blood pressures in the control condition compared to the same pressures after performing 3-hours of sitting broken up by micro-doses of physical activity.

    Time frame: Within 24 hours of sitting (Day 1) or within 24 hours of micro-doses of physical activity (Day 2). Days performed in a randomized order.

  2. Change in superficial femoral artery blood flow patterns

    The change in superficial femoral artery shear rate, ante-grade and retrograde flow (measured by femoral ultrasound) from baseline to 3 hours of sitting in the control condition compared to performing 3-hours of sitting broken up by micro-doses of physical activity.

    Time frame: Within 3 hours of sitting (Day1) or within 3 hours of micro-doses of physical activity (Day 2). Days performed in a randomized order.

Other outcomes

  1. Time course of change in endothelial function of the superficial femoral artery

    The time course of change in endothelial function of the superficial femoral artery (as measured by the change in flow mediated dilation at each time point compared to baseline in response to reactive hyperaemia using ultrasound) after each hour of sitting in the control condition compared to the micro-doses of physical activity condition.

    Time frame: Within 1 hour, 2 hours and 3 hours of sitting (Day1) or within 1 hour, 2 hours and 3 hours of micro-doses of physical activity (Day 2). Days performed in a randomized order.

  2. Change in central arterial stiffness

    Change in central arterial stiffness as measured by carotid-femoral pulse wave velocity (using arterial tonometry) from baseline to 3 hours of sitting in the control condition compared to performing 3-hours of sitting broken up by micro-doses of physical activity.

    Time frame: Within 3 hours of sitting (Day1) or within 3 hours of micro-doses of physical activity (Day 2). Days performed in a randomized order.

  3. Time course of change in superficial femoral artery blood flow patterns

    The time-course of changes in superficial femoral artery shear rate, antegrade and retrograde flow (measured by ultrasound of the femoral artery) every 30-minutes from baseline to 3 hours of sitting in the control condition compared to compared to every 30-minutes from baseline to 3 hours of sitting broken up by micro-doses of physical activity.

    Time frame: Within 30, 60, 90, 120, 150 and 180 minutes of sitting (Day1) or within 30, 60, 90, 120, 150 and 180 minutes of sitting broken up by micro-doses of physical activity (Day 2). Days performed in a randomized order.

  4. Change in endothelial microparticles

    The change in endothelial microparticles (CD62E+, CD31+, CD42b-) from baseline to post-3 hours of sitting in the control condition compared to performing 3-hours of sitting broken up by micro-doses of physical activity.

    Time frame: Within 3 hours of sitting (Day1) or within 3 hours of micro-doses of physical activity (Day 2). Days performed in a randomized order.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — Following study completion, the results will be published with mean data only and participants identities will remain undisclosed.

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 4, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05553223
Responsible party
Neil Eves (Professor, University of British Columbia) — Principal investigator
First posted
Sep 23, 2022
Start date
Oct 12, 2022
Primary completion
Sep 1, 2026 (estimated)
Completion
Sep 1, 2026 (estimated)
Last update
Apr 4, 2025

Study contacts

Neil Eves, PhD
Contact
neil.eves@ubc.ca
250-807-9676

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion